Altria/NJOY Deal Rationale

Altria recently agreed to acquire NJOY for up to $3.25B, with PWP and Moelis doing the heavy lifting on advising Altria and NJOY, respectively. It seems like a way overpriced move for Altria to be paying such an amount for a company with only 3% of the US vape market share, even if NJOY's trump card is that they have FDA approval for their products which the No. 1 and 2 market leaders in the US are struggling with. Considering that Altria has an IP-sharing agreement with Juul, why don't they just develop an in-house product rather than spend such a premium acquiring NJOY, especially after the whole Juul fiasco? Would love to hear some more discussion about this.

19 Comments
 
Most Helpful

In the C&R space but not an alcohol & tobacco banker so could be wrong, but it seems like the major roadblock in the vaping space is FDA approval - the feds have been super slow with approving vaping products, and NJOY has the only pod-based vape that's FDA authorized, so Altria likely saw the acquisition as more of an IP acquisition that allows them to skip the roadblocks they'd face with developing their own technology. The 3% market share isn't probably too concerning for Altria, given their brand image and marketing power as one of the tobacco giants. 

Also anyone know which specific bankers were working on the deal?

 

Hot take but the Juul investment wasn't as bad as it seems. Most importantly, with the Juul investment Altria ensured the next generation's market for nicotine. In the US, Juul's made e-cigarettes as iconic and commonplace among the younger generation as Marlboro Reds were to older smokers. The way I see it, Altria paid $12B to secure an entire generation of future smokers.

 

Ea error aut neque non minima ea nostrum. Quo atque ex eius aut eveniet repudiandae. Quam et quasi est magni quis voluptas.

Quis alias eaque quo. Odio voluptatum ducimus est quibusdam quod. Voluptatem blanditiis error tenetur rerum autem rerum sed reiciendis. Ipsam asperiores nesciunt ut eveniet autem ratione nihil.

Dolor amet et est quia laborum perspiciatis. Rerum itaque voluptatem dolore et voluptatem. Voluptatem perspiciatis aperiam ducimus impedit.

Ut rerum pariatur maiores aut vero praesentium quod. Labore quis enim praesentium id. Quae molestiae molestias autem. Sapiente sunt quam commodi eos impedit harum qui.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.2%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 01 98.8%
  • Evercore 01 98.2%
  • BMO Capital Markets 12 97.6%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 05 98.2%
  • JPMorgan No 97.7%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (43) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (75) $151
  • Intern/Summer Analyst (65) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
kanon's picture
kanon
99.0
4
Secyh62's picture
Secyh62
99.0
5
DrApeman's picture
DrApeman
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
CompBanker's picture
CompBanker
98.9
8
dosk17's picture
dosk17
98.9
9
GameTheory's picture
GameTheory
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”